2006
Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer
Abu-Khalaf MM, Juneja V, Chung GG, DiGiovanna MP, Sipples R, McGurk M, Zelterman D, Haffty B, Reiss M, Wackers FJ, Lee FA, Burtness BA. Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer. Breast Cancer Research And Treatment 2006, 104: 341-349. PMID: 17051423, DOI: 10.1007/s10549-006-9413-7.Peer-Reviewed Original ResearchConceptsLeft ventricular ejection fractionEnd of chemotherapyEquilibrium radionuclide angiographyBreast cancerAdjuvant therapySequential doxorubicinCardiac functionIpsilateral axillary lymph nodesHigh-risk breast cancerRisk breast cancerClinical heart failureInitiation of chemotherapyAxillary lymph nodesVentricular ejection fractionEnd of therapyLong-term cardiotoxicityMedian absolute changeEligible patientsFilgrastim supportLate cardiotoxicityAxillary nodesAsymptomatic declineEjection fractionHeart failureLymph nodes
1987
Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy Seven-year experience using serial radionuclide angiocardiography
Schwartz R, McKenzie W, Alexander J, Sager P, D'Souza A, Manatunga A, Schwartz P, Berger H, Setaro J, Surkin L, Wackers F, Zaret B. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy Seven-year experience using serial radionuclide angiocardiography. The American Journal Of Medicine 1987, 82: 1109-1118. PMID: 3605130, DOI: 10.1016/0002-9343(87)90212-9.Peer-Reviewed Original ResearchConceptsClinical congestive heart failureCongestive heart failureVentricular ejection fractionAbsolute left ventricular ejection fractionLeft ventricular ejection fractionHeart failureEjection fractionDoxorubicin therapyMild congestive heart failureClinical predictor variablesDiscontinuation of doxorubicinTotal cumulative dosageHigh-risk patientsHigh-risk subsetMajority of patientsHigh cumulative doseCommunity hospital settingProportional hazards regressionSeven-year experienceCommunity hospital environmentSerial radionuclideLast followVentricular dysfunctionClinical outcomesRoutine therapy
1983
Serial radionuclide assessment of doxorubicin cardiotoxicity in cancer patients with abnormal baseline resting left ventricular performance
Choi B, Berger H, Schwartz P, Alexander J, Wackers F, Gottschalk A, Zaret B. Serial radionuclide assessment of doxorubicin cardiotoxicity in cancer patients with abnormal baseline resting left ventricular performance. American Heart Journal 1983, 106: 638-643. PMID: 6613807, DOI: 10.1016/0002-8703(83)90080-7.Peer-Reviewed Original ResearchConceptsLeft ventricular ejection fractionVentricular ejection fractionCongestive heart failureLeft ventricular performanceVentricular performanceEjection fractionAbnormal baselineHeart failureDoxorubicin therapyDoxorubicin cardiotoxicityRadionuclide angiocardiographyAbnormal left ventricular ejection fractionFinal left ventricular ejection fractionAntecedent cardiovascular diseaseSerial radionuclide studiesFirst-pass radionuclide angiocardiographyIdentification of patientsUse of doxorubicinSafe discontinuationThoracic radiationVentricular functionCancer patientsCumulative doseCardiovascular diseaseRadionuclide assessment